KMT2A and acute myeloid leukemia: A report by Li Z et al. corroborates our data by demonstrating that FTO is elevated in MLL-rearranged AML and, among non-MLL-rearranged AMLs, FTO is expressed at a significantly higher level in t (15;17) AML and not in t (8;21), i.e., AML1-ETO and inv (16) AMLs [19].